Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6793 in healthy volunteers and COPD patients
NCT05662033Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AZD6793 in chronic obstructive pulmonary disease (COPD) (12 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events, Vital Signs and 7 more. Started Dec 2022; status: completed.
02
Drugs
AZD6793
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05662033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662033.